PDGFRA and gastrointestinal stromal tumor: The FDA has approved avapritinib as a treatment for adult patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) that harbor a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.